Analyst firms · Jefferies · APLS
Jefferies APLS price target and rating history
Apellis Pharmaceuticals Inc. (APLS) · Health Care
Jefferies rates Apellis Pharmaceuticals Inc. (APLS) Buy with a $80 price target, as of its latest action on Feb 5, 2024. It has published 3 rating actions on APLS since August 2021, including 1 upgrade and 1 downgrade. Across 3 firms with a APLS price target in the last 12 months, the median target is $28.
- Current rating
- Buy
- Price target
- $80
- Median target, all firms
- $28
- Actions on APLS
- 3
Jefferies price target on APLS
Every Jefferies rating on APLS
- Feb 5, 2024
- Nov 10, 2022
- Aug 19, 2021
How other firms rate APLS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Roth Capital | Buy | $31 | Mar 13, 2026 |
| Barclays | Equal Weight | $24 | Jan 28, 2026 |
| BofA Securities | Buy | $28 | Jan 21, 2026 |
Questions about Jefferies and APLS
- What is Jefferies's price target for APLS?
- Jefferies's latest stated price target for Apellis Pharmaceuticals Inc. (APLS) is $80, from its action on Feb 5, 2024.
- What is Jefferies's rating on APLS?
- Jefferies rates APLS Buy, a bullish rating, as of Feb 5, 2024.
- When did Jefferies last change its view on APLS?
- On Feb 5, 2024, Jefferies upgrades to Buy from Hold, price target $68 to $80.
- How does Jefferies's APLS target compare with other analysts?
- Across 3 firms with a APLS price target in the last 12 months, the median target is $28.
More APLS rating histories
All Jefferies ratingsAPLS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.